Literature DB >> 9700324

The street value of prescription drugs.

A Sajan1, T Corneil, S Grzybowski.   

Abstract

BACKGROUND: Although most physicians are aware of the potential for abuse and resale of prescribed medications, little has been done to document it. The purpose of this study was to determine which prescription drugs have street value, what that value is and why these drugs are used.
METHODS: A descriptive cross-sectional survey using a semistructured interview technique was carried out on 2 weekdays (Mar. 10 and Apr. 1, 1997) in Vancouver's Downtown Eastside. A total of 58 users and dealers of prescription sedative/hypnotic and narcotic drugs were approached. Information collected included the demographic characteristics of those interviewed, the common street names of the drugs of interest, and their value and method of use.
RESULTS: Thirty-two people agreed to participate in the study (participation rate 55%), 7 of whom were dealers. The range in price of sedative/hypnotic drugs was $0.10 to $2. For narcotic drugs the range was much greater, at $0.25 to $75. Descriptive analysis identified the minimum and maximum price and the mode of each preparation. Among the weak narcotic drugs the index drug (highest in demand on the street) was Tylenol No. 3 and among the more potent narcotics, MS Contin 30 mg.
INTERPRETATION: A wide variety of prescription sedative/hypnotic and narcotic drugs are available on the street. The mark-up from pharmacy cost can be considerable. Factors influencing pricing include the relative inexperience of the buyer, the availability of illicit narcotics, the current street supply of prescription medications and the time of the month (before or after issue of social assistance cheques).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700324      PMCID: PMC1229518     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  1 in total

Review 1.  Prescription drug abuse.

Authors:  J Finch
Journal:  Prim Care       Date:  1993-03       Impact factor: 2.907

  1 in total
  11 in total

1.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

2.  Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.

Authors:  Yulin Hswen; Amanda Zhang; John S Brownstein
Journal:  Prev Med       Date:  2020-04-27       Impact factor: 4.018

Review 3.  Drug Misuse in the Veterinary Setting: an Under-recognized Avenue.

Authors:  Akhil Anand; Avinash Hosanagar
Journal:  Curr Psychiatry Rep       Date:  2021-01-06       Impact factor: 5.285

4.  Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.

Authors:  Vincent Pradel; Catherine Delga; Frank Rouby; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

5.  Wayward prescriptions: costs of fraud in payor plans.

Authors:  Thomas Kaye
Journal:  Am Health Drug Benefits       Date:  2008-07

6.  Increases in the availability of prescribed opioids in a Canadian setting.

Authors:  B Nosyk; B D L Marshall; B Fischer; J S G Montaner; E Wood; T Kerr
Journal:  Drug Alcohol Depend       Date:  2012-04-04       Impact factor: 4.492

7.  Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women.

Authors:  Gina Ogilvie; Mel Krajden; Juanita Maginley; Judy Isaac-Renton; Greg Hislop; Ruth Elwood-Martin; Chris Sherlock; Darlene Taylor; Michael Rekart
Journal:  CMAJ       Date:  2007-08-28       Impact factor: 8.262

8.  Investigation of systems to prevent diversion of opiate drugs in general practice in the UK.

Authors:  R Baker; P Moss; D Upton; J Pankhania
Journal:  Qual Saf Health Care       Date:  2004-02

9.  Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.

Authors:  Timothy J Ives; Paul R Chelminski; Catherine A Hammett-Stabler; Robert M Malone; J Stephen Perhac; Nicholas M Potisek; Betsy Bryant Shilliday; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2006-04-04       Impact factor: 2.655

10.  Crowdsourcing black market prices for prescription opioids.

Authors:  Nabarun Dasgupta; Clark Freifeld; John S Brownstein; Christopher Mark Menone; Hilary L Surratt; Luke Poppish; Jody L Green; Eric J Lavonas; Richard C Dart
Journal:  J Med Internet Res       Date:  2013-08-16       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.